Table 2.

Continuous treatment with veliparib and olaparib as well as intermittent treatment with olaparib delayed tumor development and extended lifespan of BRCA1-deficient mice

VeliparibOlaparib
Continuous treatment, mg/kg diet0 (n = 15)100 (n = 16)0 (n = 17)200 (n = 17)
Average age of first palpable tumor, wk27.6 ± 0.530.0 ± 0.6b28.4 ± 0.934.9 ± 1.1c
Average lifespan, wk30.8 ± 0.733.2 ± 0.6a31.6 ± 1.038.6 ± 1.4a
Olaparib
Continuous treatment, mg/kg diet0 (n = 14)100 (n = 14)0 (n = 17)50 (n = 14)0 (n = 19)25 (n = 20)
Average age of first palpable tumor, wk29.5 ± 1.032.7 ± 0.8a27.9 ± 1.131.4 ± 1.0a28.1 ± 0.729.7 ± 0.7
Average lifespan, wk33.7 ± 0.838.0 ± 0.8b32.1 ± 1.335.1 ± 1.032.5 ± 0.734.0 ± 0.8
Olaparib
Intermittent treatment, mg/kg diet0 (n = 19)200 (n = 18)
Average age of first palpable tumor, wk29.9 ± 1.135.6 ± 1.0c
Average lifespan, wk35.5 ± 1.139.4 ± 1.1a

NOTE: In the continuous feeding and dose de-escalation studies, mice were fed with control, veliparib (100 mg/kg) or olaparib (200, 100, 50, and 25 mg/kg) diet starting when mice were 10 weeks old. In the intermittent study, mice were fed with control diet or cycled through 2 weeks of 200 mg olaparib/kg diet followed by 4 weeks of control diet. All mice were palpated for tumors weekly for tumor development. Litter-matched controls were used for each of the studies.

  • aP < 0.05 versus control.

  • bP < 0.004 versus control.

  • cP < 0.001 versus control.